Certified by Founder
Lodge
Ankyra Therapeutics
start up
United States
- Boston, Massachusetts
- 12/11/2021
- Series B
- $45,000,000
Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response
- Industry Biotechnology Research
- Website https://ankyratx.com/
- LinkedIn https://www.linkedin.com/company/ankyratx/about/
Related People
Howard KaufmanFounder
United States -
Boston, Massachusetts
Experienced Chief Medical Officer with a demonstrated history of working in academic medicine and the biotechnology industry. Skilled in Cancer Research, Biotechnology, Healthcare Management, Healthcare, and Life Sciences. Strong healthcare services professional with considerable expertise in cancer immunotherapy and drug development.
TrialClinIQ | $150,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
IC Realtime | $2,000,000 | (Apr 29, 2026)
Golden Child | $37,000,000 | (Apr 29, 2026)
Hypervision Surgical | $22,962,410 | (Apr 29, 2026)
dehaze | $3,746,192 | (Apr 29, 2026)
Clarasight | $11,500,000 | (Apr 29, 2026)
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)